Voyager spells out its $92M IPO pitch as Wall Street sours on biotech

Gene therapy developer Voyager Therapeutics is angling for as much as $92 million in a planned IPO, braving choppy waters for biotech after a string of disappointing debuts for life sciences companies. The company, a 2014 Fierce 15 honoree, is planning to offer about 4.7 million shares at between $15 and $17 each, setting aside another 703,125 shares for its underwriters to cover overalotments and trading under "VYGR" thereafter. Voyager's scheduled IPO comes amid an increasingly tough climate for biotech debutantes, as MyoKardia ($MYOK), Dimension Therapeutics ($DMTX), CytomX Therapeutics ($CTMX) and others have all priced at significant discounts over the past month. Voyager's lead program is a potential treatment for Parkinson's disease, and the company is working with Sanofi ($SNY) in a collaboration worth up to $845 million. More

Suggested Articles

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.

The site brings together all the units involved in the identification and support of promising drug development projects.

Pfizer is deepening its already long-term investment and partnership strategy with U.K.-based biotech Mission.